The first SightGlass Vision myopia spectacles are starting to reach the market as EssilorLuxottica and CooperCompanies announce their joint venture has commenced operation.
Their collaboration accelerates the commercialisation of novel spectacle lens technologies to expand the myopia management category.
SightGlass Vision’s trademark Diffusion Optics Technology incorporates thousands of micro-dots into the lens that softly scatter light to reduce contrast on the retina, which is intended to reduce myopia progression in children.
Mr Norbert Gorny, co-chief operating officer at EssilorLuxottica, said the company was “thrilled” to see the progress of the innovative product.
“As a global leader with a 30-year track record in myopia research, we have been developing the myopia management category for more than a decade. As such, we are thrilled to see our joint venture with CooperCompanies come to life as SightGlass Vision begins to operate and the first products start to reach the market.
“Together with eyecare professionals, we will be able to grow awareness about existing solutions and improve access to technologies that can help children today and in their future lives,” Gorny said.
Mr Dan McBride, chief operating officer and general counsel at CooperCompanies, shared Gorny’s excitement in growing the overall myopia management category.
“Adding spectacle lenses with SightGlass Vision technology to our portfolio of myopia management products translates into better eyesight and brighter lives for countless children,” he said.
“SightGlass Vision’s commitment to clinically based performance fits well with CooperVision, which has conducted the world’s longest-running myopia management clinical study and is committed to establishing myopia management as a standard of care for affected children.”
The last several decades have seen a steady rise in the prevalence of myopia worldwide, notably under the effect of lifestyle changes. Today affecting 2.6 billion people globally, it is estimated that nearly 5 billion people – half the world’s population – will be myopic by 2050.
Research shows myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.
More reading
New data confirms it’s never too late to start myopia treatment
CooperVision and Essilor announce JV for acquisition of myopia spectacle lens
WCO and CooperVision develop myopia management resource
